To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy Participants

A Phase 1, Open-label, Single-arm Study to Investigate the Effect of Retatrutide on Metoprolol Pharmacokinetics in Healthy Participants

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06808802

Enrollment

Registered

2025-02-05

Start date

2025-02-03

Completion date

2025-04-15

Last updated

2025-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Brief summary

The purpose of this study J1I-MC-GZQE is to measure the effect of retatrutide on the pharmacokinetics (PK) of metoprolol in healthy participants.

Interventions

DRUGRetatrutide

Administered subcutaneously (SC)

DRUGMetoprolol

Administered orally

Study design

Allocation

Intervention model

SEQUENTIAL

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

21 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* Are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and vital signs * Have a body mass index (BMI) within the range 22.0 to 35.0 kilogram per square meter (kg/m2) (inclusive) at screening

Exclusion criteria

* Have history of diabetes (except gestational diabetes) or current diagnosis of diabetes (any form), or have glycated hemoglobin (HbA1c) greater than or equal to (≥) 6.5% (48 millimole/mole (mmol/mol) * Have a mean supine screening pulse rate of less than 45 or greater than 100 beats per minute (bpm) from 2 assessments. If a repeat measurement (mean of 2 assessments) shows values within the range of 45 to 100 bpm, the participant may be included in the trial * Have significant history of or current cardiovascular, respiratory, hepatic, renal, GI, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study drug; or of interfering with the interpretation of data * Had any of the following cardiovascular conditions prior to screening: acute myocardial infarction, cerebrovascular accident, unstable angina, or hospitalization due to congestive heart failure

Design outcomes

Primary

Measure	Time frame	Description
Pharmacokinetics (PK): Area Under Concentration From Time Zero to Infinity (AUC[0-∞]) of Metoprolol	Day 1 to Day 3	PK: AUC (0-∞) of Metoprolol
Pharmacokinetics (PK): AUC (0-∞) of Metoprolol with Retatrutide	Day 9 to Day 11	PK: AUC (0-∞) of Metoprolol with Retatrutide
PK: Maximum Concentration (Cmax) of Metoprolol	Day 1 to Day 3	PK: Cmax of Metoprolol
PK: Cmax of Metoprolol with Retatrutide	Day 9 to Day 11	PK: Cmax of Metoprolol with Retatrutide

Secondary

Measure	Time frame
Number of Participants with an Incidence of Treatment Emergent Adverse Events TEAEs (TEAEs)	Baseline to Day 44

Countries

Singapore

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026